Search results for "Sclerosis"

showing 10 items of 1583 documents

The predictive role of atherogenic dyslipidemia in subjects with non-coronary atherosclerosis

2009

Abstract Background Recent findings have suggested that subjects with non-coronary atherosclerosis may show elevated prevalence of atherogenic dyslipidemia, including higher triglyceride levels, reduced HDL-cholesterol concentrations and increased levels of small, dense low-density lipoproteins (LDL). These three lipid abnormalities constitute the so-called “atherogenic-lipoprotein-phenotype” (ALP) but its predictive role in these patients still remains to be established. Methods We performed a 2-year follow-up study to assess clinical and biochemical predictors of cardiovascular events in 44 male patients (64 ± 5 years, BMI: 27 ± 3), 26 with peripheral arterial disease and 18 with abdomina…

Malemedicine.medical_specialtyMultivariate analysis1303 BiochemistryClinical Biochemistry10265 Clinic for Endocrinology and Diabetology610 Medicine & health1308 Clinical Biochemistry2704 Biochemistry (medical)Biochemistrychemistry.chemical_compoundRisk Factorsatherogenic dyslipidemiaInternal medicineDiabetes mellitusmedicineHumansFamily historyCoronary atherosclerosisDyslipidemiasPeripheral Vascular DiseasesUnivariate analysisTriglyceridebusiness.industryBiochemistry (medical)Cholesterol LDLGeneral MedicineMiddle AgedAtherosclerosismedicine.diseaseAbdominal aortic aneurysmPeripheralPhenotypechemistryCase-Control StudiesMultivariate AnalysisCardiologyAtherosclerosis HDL-cholesterol Triglycerides Small dense LDL Atherogenic lipoprotein phenotypebusinessAortic Aneurysm AbdominalFollow-Up Studies
researchProduct

Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone

2011

none 25 no Abstract OBJECTIVES: To evaluate the incidence and dose-dependency of mitoxantrone (MTX)-associated acute myelocytic leukemia (AML) in the network of Italian multiple sclerosis (MS) clinics. METHODS: We performed a multicenter retrospective cohort study of patients treated with MTX in MS centers under the Italian national health care system between 1998 and 2008. Demographic, disease, treatment, and follow-up information were collected using hospital records. RESULTS: Data were available for 3,220 patients (63% women) from 40 Italian centers. Follow-up (mean ± SD) was 49 ± 29 months (range 12-140 months). We observed 30 cases of AML (incidence 0.93% [95% confidence interval 0.60%…

Malemedicine.medical_specialtyMyeloidmitoxantrone; acute myelocytic leukemia; multiple sclerosisPopulationmultiple sclerosisStatistics NonparametricmitoxantroneFollow-Up StudieArts and Humanities (miscellaneous)Retrospective StudieInternal medicineMultiple SclerosimedicineHumansmultiple sclerosis leukemia mitoxantroneProspective cohort studyeducationRetrospective StudiesAgedAnalgesicseducation.field_of_studyMitoxantroneCumulative dosebusiness.industryMultiple sclerosisIncidence (epidemiology)leukemiaMyeloid leukemiaRetrospective cohort studymedicine.diseaseConfidence intervalSurgeryLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureItalyCohortSettore MED/26 - NeurologiaAnalgesicFemaleNeurology (clinical)acute myelocytic leukemiaMitoxantronebusinessFollow-Up Studiesmedicine.drugHuman
researchProduct

PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study.

2009

Phospholipid transferprotein (PLTP) mediates both net transfer and exchange of phospholipids between different lipoproteins. Although many studies have investigated the role of PLTP in atherogenesis, the role of PLTP in atherosclerotic diseases is unclear. We investigated the association of serum PLTP activity with the incidence of a combined endpoint (myocardial infarction and cardiovascular death) and its relation to other markers of atherosclerosis in 1,085 patients with angiographically documented coronary artery disease (CAD). In the median follow-up of 5.1 years, 156 patients had suffered from the combined endpoint of myocardial infarction or cardiovascular death including 47 of 395 p…

Malemedicine.medical_specialtyMyocardial InfarctionQD415-436Coronary Artery DiseaseKaplan-Meier Estimatelipid transfer proteinsBiochemistryCoronary artery diseasechemistry.chemical_compoundEndocrinologyRisk FactorsInternal medicinePhospholipid transfer proteinmedicineHumansMyocardial infarctionRisk factorPhospholipid Transfer Proteins3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitorsAgedCholesterolbusiness.industryProportional hazards modelConfoundingCase-control studyCell BiologyMiddle Agedmedicine.diseaseAtherosclerosisPrognosisEndocrinologychemistryCase-Control StudiesCardiologyFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPatient-Oriented and Epidemiological ResearchFollow-Up StudiesJournal of lipid research
researchProduct

Effect of high-caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis

2020

Recent publications showed that circulating neurofilaments (Nfs) may be used as a diagnostic biomarker distinguishing amyotrophic lateral sclerosis (ALS) from ALS mimics with high sensitivity and specificity.1–3 Furthermore, it has been shown that patients with higher Nf levels show faster disease progression1 and shorter survival.2 3 Nf levels remain rather stable during the course of disease.2 Current literature suggests that the diagnostic value of neurofilament light chains (NfL) and phosphorylated neurofilament heavy chains in cerebrospinal fluid is about equal, whereas in blood NfL seems to be superior.4 In this study, we investigated the effect of a high-caloric fatty diet (HCFD) on …

Malemedicine.medical_specialtyNeurofilament[SDV]Life Sciences [q-bio]blood [Neurofilament Proteins]PlaceboDiet High-FatGastroenterology03 medical and health sciencesblood [Amyotrophic Lateral Sclerosis]0302 clinical medicineNeurofilament ProteinsInternal medicinePost-hoc analysismedicineHumansddc:610Amyotrophic lateral sclerosisMESH: Neurofilament ProteinsComputingMilieux_MISCELLANEOUSMESH: Amyotrophic Lateral SclerosisRandomized Controlled Trials as TopicMESH: HumansMESH: Middle Agedbusiness.industryTherapeutic effectAmyotrophic Lateral SclerosisMiddle Agedmedicine.diseaseMESH: Male3. Good healthRiluzole[SDV] Life Sciences [q-bio]Psychiatry and Mental healthMESH: Diet High-FatMESH: Randomized Controlled Trials as TopicTolerabilitystatistics & numerical data [Randomized Controlled Trials as Topic]motor neuron diseasePopulation studySurgeryFemaleNeurology (clinical)businessMESH: Female030217 neurology & neurosurgerymedicine.drug
researchProduct

Clinical profile of motor neuron disease patients with lower urinary tract symptoms and neurogenic bladder

2017

Introduction: Lower urinary tract symptoms (LUTS) are frequent in motor neuron disease (MND) patients, but clinical factors related to them are unknown. We describe differences in LUTS among MND phenotypes and their relationship with other clinical characteristics, including prognosis. Methods: For this study, we collected clinical data of a previously published cohort of patients diagnosed with classical amyotrophic lateral sclerosis (cALS), progressive muscular atrophy (PMA) or primary lateral sclerosis (PLS) with and without LUTS. Familial history was recorded and the C9ORF72 expansion was analysed in the entire cohort Patients were followed-up for survival until August 2016. Results: Fi…

Malemedicine.medical_specialtyNeurogenic bladder030232 urology & nephrologyDiseaseMuscular Atrophy Spinal03 medical and health sciencesSex Factors0302 clinical medicineLower Urinary Tract SymptomsLower urinary tract symptomsC9orf72Primary lateral sclerosisInternal medicinemedicineHumansLower urinary tract symptomsMotor neuron diseaseMotor Neuron DiseaseUrinary Bladder NeurogenicFamily historyAmyotrophic lateral sclerosisAgedPrimary Lateral SclerosisC9orf72 Proteinbusiness.industryAmyotrophic Lateral SclerosisMiddle AgedProgressive muscular atrophyPrognosismedicine.diseaseAmyotrophic lateral sclerosisSurvival AnalysisSurgeryUrodynamicsCross-Sectional StudiesPhenotypeNeurologyProgressive muscular atrophyAmyotrophic lateral sclerosis Lower urinary tract symptoms Motor neuron disease Neurogenic bladder Primary lateral sclerosis Progressive muscular atrophy UrodynamicsMultivariate AnalysisCohortFemaleNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Plasma cortisol level in amyotrophic lateral sclerosis

2015

Background. Amyotrophic Lateral sclerosis (ALS) is associated with a significant distress, being linked to changes in hypothalamic-pituitary-adrenal axis activity. A loss of cortisol circadian rhythmicity in ALS patients was suggested, while more recently an increased plasma cortisol level in the disease has been reported. Objective. To assay the circadian plasma cortisol level in ALS and to study its relationship with the clinical phenotype and the rate of disease progression. Patients and methods. 135 ALS patients (Bulbar, 33; Spinal, 102; M/F = 1.73) and 110 controls (not affected by neurological or psychiatric disorders, free of drugs; M/F = 1.75) were recruited. Disease progression was…

Malemedicine.medical_specialtyNeurologyHydrocortisonemedicine.medical_treatmentCortisolInternal medicineALSFRS-RmedicineHumansCircadian rhythmAmyotrophic lateral sclerosisAgedHydrocortisoneMorningbusiness.industryAmyotrophic Lateral SclerosisBiomarkerMiddle Agedmedicine.diseaseCircadian RhythmSteroid hormoneEndocrinologyNeurologyDisease ProgressionBiomarker (medicine)FemaleNeurology (clinical)ALSbusinessBiomarkersmedicine.drugHormoneJournal of the Neurological Sciences
researchProduct

REM sleep behavior disorder and periodic leg movements during sleep in ALS

2017

Objective To assess sleep characteristics and the occurrence of abnormal muscle activity during sleep, such as REM sleep without atonia (RSWA), REM sleep behavior disorder (RBD), and periodic leg movements during sleep (PLMS), in patients with amyotrophic lateral sclerosis (ALS). Methods A total of 41 patients with ALS and 26 healthy subjects were submitted to clinical interview and overnight video-polysomnography. Results A total of 22 patients with ALS (53.6%) reported poor sleep quality. Polysomnographic studies showed that patients with ALS had reduced total sleep time, increased wakefulness after sleep onset, shortened REM and slow-wave sleep, and decreased sleep efficiency, compared t…

Malemedicine.medical_specialtyNeurologyperiodic leg movementPolysomnography[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologySleep StagePolysomnographyREM Sleep Behavior Disorderrapid eye movement sleep without atoniaNon-rapid eye movement sleepREM sleep behavior disorder03 medical and health sciences0302 clinical medicineInsomniamedicineHumansamyotrophic lateral sclerosisleepComputingMilieux_MISCELLANEOUSSlow-wave sleepAgedmedicine.diagnostic_test[SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior[SCCO.NEUR]Cognitive science/NeuroscienceAmyotrophic Lateral Sclerosis[SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive SciencesGeneral MedicineMiddle Agedmedicine.diseaseSleep in non-human animals3. Good healthNocturnal Myoclonus Syndrome030228 respiratory systemItalyNeurologyAnesthesiarapid eye movement sleep behavior disorderFemaleSettore MED/26 - NeurologiaSleep StagesNeurology (clinical)medicine.symptomSleep onsetPsychology030217 neurology & neurosurgeryHuman
researchProduct

Critical limb ischaemia is characterised by an increased production of whole blood reactive oxygen species and expression of TREM-1 on neutrophils

2013

Atherosclerosis is a chronic inflammatory process involving polymorphonuclear neutrophils (PMN) and formation of reactive oxygen species (ROS). The aim of the present study was to investigate the phenotype of inflammatory cells in regard to the expression of triggering receptor expressed on myeloid cells (TREM)-1 and its soluble form (sTREM-1) as well as its relationship with oxidative stress in peripheral artery disease (PAD) patients.In total 90 patients with PAD (N = 30 intermittent claudication (IC)300 m absolute walking distance, N = 30 IC300 m absolute walking distance, N = 30 critical limb ischaemia (CLI)) and 30 control persons were included. ROS formation was measured at basal or s…

Malemedicine.medical_specialtyNeutrophilsWalkingmedicine.disease_causeMonocytesFlow cytometryPeripheral Arterial DiseaseBasal (phylogenetics)IschemiaRisk FactorsInternal medicinePrevalencemedicineHumansReceptors ImmunologicReceptorAgedWhole bloodchemistry.chemical_classificationReactive oxygen speciesMembrane Glycoproteinsmedicine.diagnostic_testbusiness.industryMiddle AgedAtherosclerosisFlow CytometryPhenotypeTriggering Receptor Expressed on Myeloid Cells-1Intermittent claudicationOxidative StressEndocrinologychemistryImmunologyDisease ProgressionFemaleEndothelium Vascularmedicine.symptomReactive Oxygen SpeciesCardiology and Cardiovascular MedicinebusinessBiomarkersOxidative stressAtherosclerosis
researchProduct

Basal ganglia calcifications and ALS syndrome.

1994

We report the case of a patient with idiopathic hypoparathyroidism and unusually large symmetrical calcifications in the basal ganglia, thalami, cerebellar hemispheres and brainstem, who clinically presented an ALS-like syndrome. We discuss the possible role of abnormal calcium metabolism in the pathogenesis of motoneuron disease.

Malemedicine.medical_specialtyPathologyNeurologyHypoparathyroidismDermatologyIdiopathic hypoparathyroidismBasal GangliaPathogenesisThalamusCerebellumBasal gangliamedicineHumansNeuroradiologybusiness.industryGeneral NeuroscienceAmyotrophic Lateral SclerosisCalcinosisGeneral MedicineSyndromeMiddle Agedmedicine.diseasePsychiatry and Mental healthnervous systemHypoparathyroidismNeurology (clinical)NeurosurgeryBrainstembusinessTomography X-Ray ComputedBrain StemItalian journal of neurological sciences
researchProduct

How to treat tumefactive demyelinating disease?

2013

Glioma-like inflammatory demyelinating lesions can be found in patients with pre-diagnosed multiple sclerosis, but they have also been described as an isolated disease entity. The initial diagnostic work-up usually includes a biopsy for histopathological analysis. However, even after unambiguous histopathologic classification, tumefactive lesions pose a therapeutic challenge. Until now, there have been no guidelines on how to treat patients with these rare and extreme lesion phenotypes. Here we report a patient with a relapsing unifocal tumefactive demyelinating lesion. The patient initially showed a good response to steroid treatment, with full clinical recovery. However, after relapse of…

Malemedicine.medical_specialtyPathologyTime FactorsBiopsymedicine.medical_treatmentDrug Administration ScheduleLesionRecurrenceInduction therapyBiopsymedicineDemyelinating diseaseHumansIn patientmedicine.diagnostic_testDrug Substitutionbusiness.industryMultiple sclerosisImmunosuppressionMiddle Agedmedicine.diseaseMagnetic Resonance ImagingRegimenTreatment OutcomeNeurologyDrug Therapy CombinationSteroidsNeurology (clinical)Radiologymedicine.symptombusinessImmunosuppressive AgentsDemyelinating DiseasesMultiple Sclerosis Journal
researchProduct